AAA shifts focus on SPECT and therapeutics to accelerate radiopharma growth
This article was originally published in Clinica
The global nuclear medicine market is, and has been, dominated by the developers of capital-intensive imaging equipment, giants such as GE, Philips and Siemens who pour millions into R&D programmes in a bid to churn out innovations and set new trends.
You may also be interested in...
Minimally invasive glaucoma surgery specialist Glaukos saw its stock leap 40% in the wake of a worldwide recall by much bigger rival Alcon of its CyPass microstent.
Roland Diggelmann will end his decade-long career at Roche Diagnostics at the end of September. The business's head of EMEA Michael Heuer will take Diggelmann's place while the search is on for his replacement.
Philips has added a new pulse oximetry platform to its patient monitoring portfolio, with the acquisition of Xhale Assurance.